Eli Lilly and Company (LLY)
| Market Cap | 592.95B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 43.19 |
| Forward PE | 23.90 |
| Dividend | $6.00 (0.91%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 6,210,317 |
| Open | 650.40 |
| Previous Close | 639.43 |
| Day's Range | 644.50 - 661.75 |
| 52-Week Range | 623.78 - 972.53 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 989.25 (+49.78%) |
| Earnings Date | Aug 7, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $989.25, which is an increase of 49.78% from the latest price.
News
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
Viking Therapeutics, Inc. VKTX is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a...
Lilly launches Mounjaro pen in India priced at $160
Eli Lilly launched the pre-filled injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India on Wednesday, stepping up competiti...
These Eli Lilly executives have been scooping up stock after its big drop
After Eli Lilly & Co. shares fell sharply in the wake of disappointing trial data for its weight-loss pill, several of its executives and board members saw an opportunity to buy.
Final Trade: LLY, ULTA, AAPL, GDX
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications.
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc AFRM is a buy. “It's at $72, it's going to $100,” he noted.
2 All-American Dividend Gems To Buy Before The Market Wakes Up
I see Las Vegas' struggles as a mirror of broader economic woes of high prices, low consumer confidence, and trade uncertainty, pressuring markets and creating slim margins for error. I believe market...
Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's price fell with a thud yesterday following underwhelming drug trial results as the markets completely ignored strong Q2 2025 results. LLY's drop is immediately reminiscent of a similar plu...
Calls of the Day: Eli Lilly, E.L.F. Beauty and CRH PLC
The Investment Committee debate the latest Calls of the Day and how to trade them.
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Eli Lilly: 50% Upside For LLY Stock?
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This pos...
Lilly's new diet drug comes up short in trials
A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegov...
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In
Eli Lilly delivered strong Q2 results, beating analyst estimates and raising guidance, driven by robust growth in Mounjaro and Zepbound sales. Despite impressive financials, the stock remains expensiv...
S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results
Major U.S. equities indexes were mixed Thursday after the overnight onset of President Trump's "reciprocal" tariffs, which increased the levies imposed on imports from a broad range of trading partner...
Eli Lilly's oral obesity treatment efficacy falls short of expectations, says BMO's Evan Seigerman
Evan Seigerman, BMO, joins 'Fast Money' to talk the latest oral obesity treatment data out of Eli Lilly.
LLY Plunges on Earnings & Weight Loss Drug Disappointment, Outlook Still Holds Optimism
"This market is priced for perfection," says Rebecca Walser (@walserwealth) and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight...
Stocks Swing Lower as Eli Lilly, Fortinet Spiral: Stock Market Today
The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.
Eli Lilly stock sell-off ‘overdone' as weight-loss pill remains ‘commercially viable'
Goldman Sachs analyst Asad Haider says investors are overreacting to the late-stage data Eli Lilly & Co (NYSE: LLY) reported for its experimental oral obesity pill, orforglipron, on Thursday. Lilly re...
Eli Lilly's Experimental Weight-Loss Pill Data Disappoints
A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegov...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used f...
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall Street] had....
Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment
Eli Lilly delivered strong Q2 results, raising full-year guidance, but shares plunged over 15% due to underwhelming Orforglipron weight loss data. Tirzepatide's explosive growth cements Lilly's domina...
Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research L...